RALEIGH, N.C., Jun. 15 (Korea Bizwire) — PRA Health Sciences (Nasdaq:PRAH), a leading global contract research organization, today announced its new Predictivv(TM) platform, the beginning of an entirely new approach on the role technology will play in the future of clinical development. The Predictivv(TM) platform will be a fully integrated solution for designing, planning and optimizing the management of global clinical studies. Designed around a unified platform that harmonizes data, processes, and people across every aspect of a clinical study, Predictivv(TM) will enable unprecedented adaptive intelligence and decision support for the ever-increasing complexities of the clinical development process.
“Predictivv(TM) is another step in PRA’s ambitious goal to change the future of clinical development,” said CEO Colin Shannon. “As we enter a new era of clinical development led by ideas like adaptive trial design and risk-based monitoring, we recognized that existing clinical-trial management solutions did not support the real-time modifications of protocols and operational plans required by adaptive models and the high risks associated with managing this complexity.”
The Predictivv(TM) platform will seamlessly bring together a series of clinical study applications representing the foundation of a true end-to-end clinical development process. Predictivv(TM) combines data input and continuous feedback from across the spectrum of the trial process, empowering decision support intelligence throughout the entire clinical lifecycle.
“One of the primary goals we established when designing the Predictivv platform was to provide the industry with unprecedented transparency into their portfolio of studies,” said Shannon. Through a proprietary analytics engine, Predictivv(TM) will not only provide transparency into all key processes and their statuses, but it will be capable of proactively identifying process and protocol deviations, enabling course corrections before risks occur.
Among the first applications that will be available in the Predictivv(TM) platform is Predictivv Connect(TM). Connect is a highly configurable solution that provides real time insights into every phase of clinical trial management, empowering clients and key stakeholders to connect and use data within their studies in an entirely new way.
With its investment in the Predictivv(TM) platform, PRA anticipates launching several new applications that focus on key aspects of clinical trial management, including areas such as site selection, patient recruitment and investigator engagement. Predictivv(TM) applications will be device independent, allowing users to explore data, uncover new insights and take action instantly from any device.
ABOUT PRA HEALTH SCIENCES
PRA Health Sciences is one of the world’s leading global contract research organizations, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. At PRA, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions(TM) model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.
CONTACT: MEDIA INQUIRIES:
Christine Rogers, Manager – Public Relations,
PHONE: +1 919.786.8463
4130 ParkLake Avenue,
Raleigh, North Carolina USA
PHONE: +1 919.786.8200
Source: PRA Health Sciences via GLOBE NEWSWIRE